Taiwan-based Boncha Bio has forged a partnership with dsm-firmenich, a nutrition, health, and beauty innovator, to advance the development of nutraceuticals with candy-capsule technology in Asia.

Dsm-firmenich is engaged in reinventing, manufacturing, and combining key nutrients, flavours, and fragrances.

The candyceuticals to be launched by the parties will provide an all-in-one supplement solution by combining diverse nutrients that conventionally don’t co-exist into a single formula.

The partnership agreement, signed at the Vitafoods Asia 2023 exhibition in Bangkok, Thailand, is intended to launch market-ready candyceuticals that offer sensory delight with health benefits.

As part of the collaboration, dsm-firmenich has secured exclusive distribution rights for Boncha Bio’s candyceuticals in key markets, including Japan and South Korea. These products will be positioned as market-ready-solutions (MRS) under the health, nutrition, and care business unit in Asia.

Dsm-firmenich APAC regional MRS lead Ling Rei-Ting said: “In Asian markets, particularly South Korea and Japan, the constant demand for novel formats and unique consumer experiences is reshaping the market.

“Consumers are leaning toward more natural, pleasurable ways to consume supplements. Our collaboration with Boncha Bio is designed to meet this demand without compromising on efficacy.”

The two companies have collaborated closely to create the NutriBurst product line which consists of soft-chew candy capsules with a centre filling.

The range was produced by combining Boncha Bio’s candyceutical technology with dsm-firmenich’s premix.

At the Vitafoods Asia 2023 Exhibition, the nutrition, health, and beauty firm formally introduced its MRS candy capsule line to its global customer base.

Boncha Bio’s candyceuticals are said to have a user-centric design with a candy-like texture experience. This increases user compliance and intake frequency to boost the sales for wellness brands, Boncha Boncha said.

In July this year, dsm-firmenich acquired the Adare Biome business unit of US-based Adare Pharma Solutions for €275m.